23 November 2015 - The U.S. FDA today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm